

CLAIMS

1. A copolymer-1 fraction substantially free of species of copolymer-1 having a molecular weight of over 40 kilodaltons.
2. A copolymer-1 fraction, wherein said fraction contains less than 5% of species of copolymer-1 having a molecular weight of over 40 kilodaltons.
3. The copolymer-1 fraction according to claim 2, wherein the fraction contains less than 2.5% of species of copolymer-1 having a molecular weight of over 40 kilodaltons.
4. The copolymer-1 fraction according to claim 2, wherein over 75% of said fraction is within a molecular weight range from about 2 kilodaltons to about 20 kilodaltons.
5. A copolymer-1 fraction, wherein said copolymer-1 has an average molecular weight of about 4 to about 8 kilodaltons.
6. A copolymer-1 fraction, wherein said copolymer-1 has an average molecular weight of about 6.25 to about 8.4 kilodaltons.
7. A composition for the treatment of multiple sclerosis, comprising
  - a pharmaceutically effective amount of a copolymer-1 fraction, wherein said fraction contains less than 5% of species of copolymer-1 having a molecular weight of over 40 kilodaltons, and
  - a pharmaceutically acceptable carrier.
8. The composition according to claim 7, wherein the

copolymer-1 fraction contains less than 2.5% of species of copolymer-1 having a molecular weight of over 40 kilodaltons.

9. The composition according to claim 7, wherein over 75% of said copolymer-1 in said fraction is within a molecular weight range of about 2 kilodaltons to about 20 kilodaltons.

10. A composition for the treatment of multiple sclerosis, comprising

a pharmaceutically effective amount of a copolymer-1 fraction, wherein said copolymer-1 in said fraction has an average molecular weight of about 4 to about 8 kilodaltons, and

a pharmaceutically acceptable carrier.

11. A composition for the treatment of multiple sclerosis, comprising

a pharmaceutically effective amount of a copolymer-1 fraction, wherein said copolymer-1 in said fraction has an average molecular weight of about 6.25 to about 8.4 kilodaltons, and

a pharmaceutically acceptable carrier.

12. A method for treating multiple sclerosis, comprising administering to a subject in need thereof a pharmaceutically effective amount of a copolymer-1 fraction, wherein said fraction contains less than 5% of species of copolymer-1 having a molecular weight of over 40 kilodaltons.

13. The method according to claim 12, wherein the copolymer-1 fraction contains less than 2.5% of species of copolymer-1 having a molecular weight of over 40 kilodaltons.

14. The method according to claim 12, wherein over 75% of said copolymer-1 in said fraction is within a molecular weight range of about 2 kilodaltons to about 20 kilodaltons.

15. A method for treating multiple sclerosis, comprising administering to a subject in need thereof a pharmaceutically effective amount of a copolymer-1 fraction, wherein said copolymer-1 in said fraction has an average molecular weight of about 4 to about 8 kilodaltons.

16. A method for treating multiple sclerosis, comprising administering to a subject in need thereof a pharmaceutically effective amount of a copolymer-1 fraction, wherein said copolymer-1 in said fraction has an average molecular weight of about 6.25 to about 8.4 kilodaltons.